SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a loss of $80.1 million in its third quarter.

The San Diego-based company said it had a loss of $1.55 per share.

The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $2.87 per share.

The biopharmaceutical company posted revenue of $71.8 million in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRTX at https://www.zacks.com/ap/MRTX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News